Novo Nordisk's high-dose Wegovy shows 20.7% weight loss in Phase 3 but falls short of Eli Lilly's Zepbound, raising questions ...

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...

FDA approves AstraZeneca's Calquence as first BTK inhibitor for first-line mantle cell lymphoma, leading BeiGene's Brukinsa ...

FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...

WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

Novartis is the latest drugmaker to sue the government for allegedly rejecting its proposed model to distribute federal drug ...

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

The EMA's human medicines committee recommended 114 medicines for approval in 2024, marking the highest number of positive ...

After seeing its Covid-19 drug fail in a Phase 3 trial last year, Shionogi on Thursday won a $375 million award from HHS to ...

Teva is the latest drugmaker to file suit against Medicare negotiations. But unlike other companies that have challenged the ...

Novartis won a potentially short-lived victory in its fight across multiple courts to keep generic versions of its ...